Multiple Sclerosis and Related Disorders

Papers
(The TQCC of Multiple Sclerosis and Related Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Sarcopenia in patients with multiple sclerosis83
Opsoclonus myoclonus syndrome in a postpartum period79
Feasibility and usability evaluation of a gamified fatigue management mobile application for persons with multiple sclerosis in everyday life69
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis67
Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis62
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series59
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study50
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression50
Involvement Peripheral Nerve System in Multiple Sclerosis49
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study48
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease48
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran47
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets47
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis47
The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia47
Missed MS or MIMS not prodromal MS: Expanding the diagnostic MS spectrum42
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America41
Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease40
Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosis39
Transcutaneous spinal cord stimulation improves postural stability in individuals with multiple sclerosis39
Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study39
Middle-age people with multiple sclerosis demonstrate similar mobility characteristics to neurotypical older adults39
Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects38
Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment38
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy38
Peripheral nerve vulnerability as risk factor for multiple sclerosis: Possible insights from Neurofibromatosis type 2 (NF2)37
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents37
Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran37
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia36
Lipid measures are associated with cognitive functioning in multiple sclerosis patients36
Effects of constraint induced movement therapy in patients with multiple sclerosis: A systematic review36
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis35
Diagnosing ‘transition’ to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians35
Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography35
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination34
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis33
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul33
Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience32
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients32
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study32
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis32
The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis30
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects30
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review30
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina30
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports30
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort30
143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry30
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study29
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS29
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya29
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis29
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?29
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis29
Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod28
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors28
“It's on the tip of my tongue!” exploring confrontation naming difficulties in patients with multiple sclerosis28
Sexual problems in MS: Sex differences and their impact on quality of life28
Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms28
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis28
Autoimmune encephalitis: A retrospective monocentric experience27
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?27
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan27
Impact of insurance status on MRI phenotypes in MS27
What telomeres teach us about MS27
MS and Disability Progression in Latin America, Africa, Asia and the Middle East: A Systematic Review27
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies27
Dietary intake and characteristics in persons with multiple sclerosis26
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial26
Cognitive outcomes in late-onset versus adult-onset Multiple Sclerosis26
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk26
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis26
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study26
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal26
30. Thalamic Volume Differentiates Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorder25
Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis25
67. Domain-Specific and Global Cognitive Impairment in Multiple Sclerosis Patients Based on Cambridge Neuropsychological Test Automated Battery25
41. Neuropathic Pain in Multiple Sclerosis25
95. Patterns of Corpus Callosum Lesions in Demyelinating Diseases of the Central Nervous System25
120. The Pathological Findings of the First Cervical Spine MRI of The Neuromyelitis Optica Spectrum Disorders Patients25
23. Vanishing Clues: A Systematic Review of Oligoclonal Band Disappearance in Multiple Sclerosis Patients after Treatment25
101. Pseudotumor Demyelinating Lesions in Inflammatory Diseases of the Central Nervous System: An Algerian Series25
165. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab24
Cross-Cultural Adaptation and Psychometric Evaluation of the Physical Activity and Disability Survey - Revised in People with Multiple Sclerosis24
134. Impact of Bowel Dysfunction, Urinary Dysfunction, and Fatigue on Quality of Life in Multiple Sclerosis24
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters24
70. Real-World Experience of Cladribine Tablets in the Treatment of Multiple Sclerosis: An Omani Cohort from Khoula Hospital24
81. Gender Difference In Egyptian Patients With Multiple Sclerosis24
Bio-Psycho-Social Model of Multiple Sclerosis (BPSMMS)24
Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study23
Barriers to Engage in Physical Activity in People with Multiple Sclerosis in Jordan23
Efficacy of Virtual Reality Interventions on Mood and Cognition in Patients with Multiple Sclerosis. a Systematic Review23
Adherence to Treatment in Multiple Sclerosis23
RETRACTED: New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-1922
Is maximal muscle strength and fatigability of three lower limb muscle groups associated with walking capacity and fatigability in multiple sclerosis? An exploratory study22
Factors contributing to falls in people with multiple sclerosis: The exploration of the moderation and mediation effects22
Cardiovascular risk estimated in individuals with multiple sclerosis: A case-control study22
Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis22
Cervical lymph node diameter reflects disease progression in multiple sclerosis22
Differences in symptoms of depression between females and males with relapsing-remitting multiple sclerosis22
Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study22
Levamisole-associated multifocal inflammatory encephalopathy: clinical and MRI characteristics, and diagnostic algorithm22
Impact of multiple sclerosis on male sexual and reproductive health22
Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study21
Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging21
Higher frequency of Human herpesvirus-6 (HHV-6) viral DNA simultaneously with low frequency of Epstein-Barr virus (EBV) viral DNA in a cohort of multiple sclerosis patients from Rio de Janeiro, Brazil21
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool21
Seroconversion rate following HBV vaccination in clinical practice: The role of age and DMT treatment21
Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review21
Effect of high frequency repetitive transcranial magnetic stimulation (rTMS) on the balance and the white matter integrity in patients with relapsing-remitting multiple sclerosis: A long-term follow-u21
The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis21
The role of pregnancy in relapsing-remitting MS prognosis: A five-year study21
Dysphagia in Relation with Depression, Anxiety, Fatigue, Sleep Quality, and Pain in Multiple Sclerosis21
Effects of photobiomodulation therapy on muscle function in individuals with multiple sclerosis20
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database20
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study20
No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.20
Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study20
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications20
Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis20
Willingness to receive a COVID-19 vaccine in people with multiple sclerosis – UK MS Register survey20
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)20
Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD19
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting mul19
Defining the prodromal phase of multiple sclerosis based on healthcare access in a Portuguese population - ProdMS study19
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model19
Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis19
Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis19
Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina19
Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study19
Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study19
Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey19
Cerebrospinal fluid indices as predictors of treatment response in autoimmune encephalitis19
Monkeypox in Multiple Sclerosis patients: Should we be alert?19
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies19
Carotid intima media thickness and multiple sclerosis18
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study18
Peripheral neuropathy and MOG-IgG: A clinical and neuropathological retrospective study18
Validation of the Self-Assessed Dynamic Gait Index in People with Multiple Sclerosis18
Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up18
Real World Study of Ocrelizumab in Multiple Sclerosis: Kuwait Experience18
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial18
Perspectives on fatigue management among veterans living with multiple sclerosis18
Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology18
Depression, Anxiety and Alexithymia in Tunisian Patients with Multiple Sclerosis18
Predictors of Progression of Multiple Sclerosis in a Sample of Egyptian Patients18
Prevalence and Clinical Characteristics of Urological Symptoms in Iranian Multiple Sclerosis Patients: Implications for Quality of Life and Management18
Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.18
An internet-based survey of synesthesia in multiple sclerosis: Incidence, characteristics and implications18
The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia18
Telehealth in Multiple Sclerosis: Fostering Quality of Life18
Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort17
Effects of submotor-threshold tibial nerve stimulation on plantarflexion torque in healthy adults and people with multiple sclerosis17
Multiple Sclerosis in Elderly Patients: When We Can Stopped Treatment?17
Using MS induced pluripotent stem cells to investigate MS aetiology17
Patients experiences when receiving diagnosis of multiple sclerosis: A qualitative systematic review17
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD17
The Effect of Rituximab on Mood Disorders in Multiple Sclerosis17
Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis17
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS17
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers17
Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls17
Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group17
Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study17
Vascular endothelial dysfunction associated with severity in multiple sclerosis17
Capacity of fullerenols to modulate neurodegeneration induced by ferroptosis: Focus on multiple sclerosis17
Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study17
Longitudinally extensive transverse myelitis with positive aquaporin-4 IgG associated with dengue infection: a case report and systematic review of cases16
The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis16
Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease16
Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes16
Burden of multiple sclerosis: impact on the patient, family and society16
Exclusion of alternative diagnoses: A component of the 2023 MOGAD criteria that belongs at the forefront, not in the background16
Prevalence and incidence of multiple sclerosis in the Netherlands16
Mitochondrial Mutations in Multiple Sclerosis Patients with Atypical Optic Neuropathy16
Comparison of vision-related quality of life in NMOSD and MOGAD16
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes16
Are we ready for CD19-targeted CAR T-cell therapies in MS?16
S3I-201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th16
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies16
Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison16
Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial16
Racial disparities in hypertension management among multiple sclerosis patients16
Altered gene expression of miR-155 in peripheral blood mononuclear cells of Multiple sclerosis patients: Correlation with TH17 frequency, inflammatory cytokine profile and autoimmunity16
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients16
153. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial16
Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients16
Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS16
Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis16
Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review16
Significant retinal microvascular impairments in multiple sclerosis assessed through optical coherence tomography angiography16
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis16
Feasibility and tolerability of portable, low-field brain MRI for patients with multiple sclerosis16
Myelopathies in patients older than 50: not to miss inflammatory etiologies.15
The effect of COVID-19 lockdowns on exercise and the role of online exercise in Australians with multiple sclerosis15
Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care15
Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelits optic spectrum disorder (NMOSD) in Sri Lanka15
Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response15
Prevalence of Urinary Tract Symptoms in Patients with Multiple Sclerosis and Health Care Seeking Behavior: A Cross Sectional Study in Riyadh, Saudi Arabia.15
Neural Substrates of Mobility and Postural Impairments in People with Multiple Sclerosis15
Social network size and mental health outcomes in youth with neuroinflammatory disorders15
Clinical Characteristics of Switching Between Disease Modifying Drugs Among a Sample of Egyptian Multiple Sclerosis Patients15
Effects of Cognitive and Motor Secondary Tasks on Gait Performance in Healthy Controls and Multiple Sclerosis Patients with and Without Fall History15
Prognosis of walking function in multiple sclerosis supported by gait pattern analysis15
Quality of life, Knowledge and Access to Treatment in Times of Economic crisis in Lebanon15
Increased healthcare utilization in the year before multiple sclerosis diagnosis15
Telemedicine and Multiple Sclerosis Management in the Era of COVID-19, Al-Azhar Experience15
The prevalence of Myocardial Infarction among Multiple Sclerosis Patients: a Systematic Review and Meta-analysis15
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants15
MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis15
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis15
Aggressive Pediatric Multiple Sclerosis: Features and therapeutic Challenges15
Linking X to MS: Immunity and demyelination on the X-chromosome in MS15
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal15
Beyond the B-cell as a treatment target in multiple sclerosis15
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab15
Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain14
The effect of cooling garments to improve physical function in people with multiple sclerosis: A systematic review and meta-analysis14
Weak grip strength among persons with multiple sclerosis having minimal disability is not related to agility or integrity of the corticospinal tract14
Self-reported fatigue impact is associated with frequency of falls and injurious falls in people with multiple sclerosis14
124. The Prevalence of Iron Overload in Patients with Multiple Sclerosis in National Guard Health Affair Hospital, Riyadh Center from 2015-202114
106. Assessment of Depression and Anxiety in Patients with Multiple Sclerosis in Morocco14
Variability of objective gait measures across the expanded disability status scale in people living with multiple sclerosis: A cross-sectional retrospective analysis14
Sleep, physical activity, and psychological outcomes in children and adolescents with pediatric onset multiple sclerosis14
Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients14
Coenzyme Q10 supplementation in multiple sclerosis; A systematic review14
Range of motion abnormalities in the lower limb joints during gait in youth with multiple sclerosis14
Allied health professionals knowledge and clinical practice in telehealth exercise behavioural change for multiple sclerosis14
Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: A new mimicker of progressive multiple sclerosis?14
High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study14
Seizures in inflammatory demyelinating disorders of the central nervous system14
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis14
79. Sustained Treatment Persistence and High Adherence to Cladribine Tablets in Multiple Sclerosis: Results from Patient Support Program in Gulf Countries14
COVID-19 in neuromyelitis optica spectrum disorder patients in Poland14
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy14
Do baseline cognitive status, participant specific characteristics and EDSS impact changes of cognitive performance following aerobic exercise intervention in multiple sclerosis?14
Update on aquaporin-4 antibody detection: the early diagnosis of neuromyelitis optica spectrum disorders14
Psychotherapy and professional psychological support in multiple sclerosis: Uncovering patients’ patterns of access and preferences14
Emerging trends in multiple sclerosis research14
Multiple Sclerosis in Middle East North Africa (MENA) Region: Challenges, Achievements and Opportunities.14
Additive beneficial effects of aerobic training and royal jelly on hippocampal inflammation and function in experimental autoimmune encephalomyelitis rats14
Connection between microstructural alterations detected by diffusion MRI and cognitive dysfunction in MS: A model-free analysis approach14
Multiple Sclerosis and biological definitions in neurodegenerative diseases14
A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy14
Validity and reliability of the Six-Minute Pegboard Ring Test for assessing functional capacity and upper limb function in persons with multiple sclerosis14
Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS)14
Predominant cognitive phenotypes in multiple sclerosis: Insights from patient-centered outcomes14
Multiple sclerosis-related heat sensitivity linked to absence of DMT prescription and subjective hand impairment but not autonomic or corticospinal dysfunction13
Humoral and cellular immune responses to SARS CoV-2 vaccination in People with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments13
Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset13
1.0853199958801